Inicio › Cáncer de hígado (carcinoma hepatocelular) › Washington
Ensayos clínicos de Cáncer de hígado (carcinoma hepatocelular) en Washington
15 estudios sobre Cáncer de hígado (carcinoma hepatocelular) buscan participantes en Washington.
Ciudades en Washington
Texto oficial del estudio (inglés)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
ReclutandoSe aceptan voluntarios sanos
Edades de 45 a 75 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Seattle
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center- Montlake, Seattle
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07227012A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0083, Seattle
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07291076GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Fred Hutchinson Cancer Center, University of Washington, Seattle
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Seattle
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06921785A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
ReclutandoFase 2
Edades de 8 en adelante · Todos los sexos · Actualizado el 27 jul 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Reclutando
Edades de 18 a 75 · Todos los sexos · Actualizado el 17 jun 2026 · NCT05486572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 may 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Virginia Mason Medical Center, Seattle
- Summit Cancer Centers - North Spokane, Spokane
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 abr 2026 · NCT05440708Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- American Oncology Network Vista Oncology Division/Physician Partner Associate, Olympia
- Northwest Medical Specialties PLLC (NWMS), Tacoma
ReclutandoFase 1
Edades de 18 a 65 · Todos los sexos · Actualizado el 16 mar 2026 · NCT07176650Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
- Seattle Children's Hospital, Seattle
ReclutandoFase 1
Edades de 1 a 26 · Todos los sexos · Actualizado el 17 feb 2026 · NCT07148050A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 nov 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.